Kanopas 10 mg (Tablet)
Unit Price: ৳ 65.00 (1 x 10: ৳ 650.00)
Strip Price: ৳ 650.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Finerenone |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Reduce risk of sustained eGFR decline
- Reduce risk of end-stage kidney disease
- Reduce risk of cardiovascular death
- Reduce risk of nonfatal myocardial infarction
- Reduce risk of hospitalization for heart failure
Pharmacology
- Nonsteroidal
- Selective antagonist of mineralocorticoid receptor (MR)
- Blocks MR mediated sodium reabsorption
- Has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors
- Completely absorbed after oral administration
- Metabolized by CYP3A4 and CYP2C8
- Excreted in urine
Dosage & Administration
- Recommended starting dosage of 10mg or 20mg orally once daily
- Increase dosage to target dose of 20mg once daily after 4 weeks
- Tablets may be taken with or without food
- For patients unable to swallow whole tablets, may be crushed and mixed with water or soft foods
Interaction
- Contraindicated with strong CYP3A4 inhibitors
- Monitor serum potassium during concomitant use with moderate or weak CYP3A4 inhibitors
- Avoid concomitant use with strong or moderate CYP3A4 inducers
Contraindications
- Contraindicated in concomitant use with strong CYP3A4 inhibitors
- Contraindicated in patients with adrenal insufficiency
Side Effects
- Adverse reactions include hyperkalemia, hypotension, and hyponatremia
Pregnancy & Lactation
- No available data on use in pregnancy
- No data on presence in human milk
- Avoid breastfeeding during treatment and for 1 day after treatment
Precautions & Warnings
- Can cause hyperkalemia
- Measure serum potassium and eGFR before initiation of treatment
- Do not initiate if serum potassium is > 5.0 mEq/L
- More frequent monitoring may be necessary for patients at risk for hyperkalemia
Use in Special Populations
- Safety and efficacy not established in patients below 18 years of age
- No overall differences in safety or efficacy observed in elderly patients
- Avoid use in patients with severe hepatic impairment
- No dosage adjustment recommended in patients with mild or moderate hepatic impairment
Overdose Effects
- Suspected overdose should be immediately interrupted
- Most likely manifestation of overdose is hyperkalemia
- Standard treatment should be initiated if hyperkalemia develops
- Unlikely to be efficiently removed by hemodialysis
Therapeutic Class
- Mineralocorticoid Receptor Antagonists
Storage Conditions
- Keep below 30°C temperature
- Keep away from light and moisture
- Keep out of the reach of children